Vitamin K2 and Arterial Calcification: Can It Remove Plaque?

Vitamin K2 has not been established as a supplement that dissolves existing arterial plaque. However, two positive randomized trials published in 2026 found slower progression of coronary calcium with MK-7-based interventions in selected patients. That is a meaningful development in the evidence.

To interpret it correctly, distinguish four questions: Did a vitamin K marker improve? Did a calcium score rise more slowly? Did plaque volume fall? And did patients have fewer heart attacks or deaths? The answers do not have to be the same.

Plaque, calcification and calcium scores

Atherosclerotic plaque can contain lipid, fibrous tissue and calcium. Coronary artery calcium, commonly measured by CT and expressed as an Agatston score, captures the calcified component. It does not describe every feature of plaque or directly measure how obstructed an artery is.

Calcium progression is therefore an imaging endpoint. A treatment that slows its increase has not necessarily removed existing calcium or reduced the volume of every plaque component. Plaque stability and clinical events require separate assessment.

That is why the phrase “unclogs arteries” is too strong for the current K2 evidence.

Why K2 is being studied

Matrix Gla protein is a vitamin-K-dependent protein involved in limiting inappropriate calcification. Vitamin K enables its carboxylation, giving researchers a plausible pathway to investigate.

Studies often measure dp-ucMGP, a marker related to vitamin K status and this pathway. A favorable change can show biological activity, but it does not automatically prove that the primary imaging or event outcome improved.

The major randomized findings side by side

The complete reports are available through AVADEC, its coronary analysis, VitaK-CAC and DANCODE.

DANCODE: what the numbers mean

DANCODE enrolled people with coronary calcium scores of at least 400. The median age was 71, and 30% of the analyzed group were women. Participants received the combination or placebo for 24 months.

Average calcium-score increase was 196 Agatston units with treatment and 248 with placebo. The between-group difference was minus 52 units, with a 95% confidence interval from minus 79 to minus 24.

Both groups still accumulated calcium. The finding is slower progression, not reversal. In the angiography subset, calcified-plaque progression was lower, while total and noncalcified plaque-volume results did not show the same benefit. Whether these imaging differences improve clinical outcomes remains a separate question.

VitaK-CAC: a different coronary population

VitaK-CAC tested MK-7 alone in patients with symptomatic coronary disease and calcium scores between 50 and 400. It therefore differs from DANCODE in baseline disease severity and the intervention.

Coronary calcium rose in both groups, with a significant difference in progression favoring MK-7. That provides another positive randomized signal while preserving the same distinction: slower accumulation does not mean existing plaque was cleared.

The two trials strengthen the case for studying MK-7 further. They do not establish the same benefit in young healthy adults or at every dose sold in combination capsules.

Why the earlier neutral results still matter

AVADEC did not significantly improve its primary aortic-valve-calcification endpoint. Its coronary secondary analysis also did not show a significant overall reduction in progression, although some subgroup findings were of interest.

This does not automatically invalidate the later studies. Trial populations, endpoints, disease stages and interventions differ. It does mean a balanced account should include both positive and neutral evidence rather than presenting a single older result as the whole field.

A secondary publication from one parent trial also should not be counted as an independent replication.

What about chronic kidney disease?

Calcification in chronic kidney disease has additional metabolic features and cannot be treated as equivalent to ordinary supplement use in a healthy adult. The K4Kidneys randomized trial did not establish a general vascular benefit from the tested K2 regimen.

Kidney disease also changes the safety assessment of magnesium and vitamin D. Do not use findings from coronary-disease trials to create an unsupervised mineral regimen for a person with impaired kidney function.

Observational dietary evidence: useful, but different

The Rotterdam study associated menaquinone intake with coronary outcomes. Dietary associations can generate hypotheses, but people with different diets also differ in other behaviors and exposures.

A food association therefore cannot identify the effect of an MK-7 capsule, and it cannot prove that increasing the dose will reproduce the association. Randomized studies help answer that intervention question more directly.

Can a D3/K2/magnesium product claim these results?

Only with careful formulation and dose context. DANCODE used a particular K2/D3 regimen; VitaK-CAC used MK-7 alone. Neither was a trial of DoNotAge Pure D3, K2 & Magnesium.

The ingredients make these studies relevant background. They do not demonstrate product-specific efficacy or establish that the magnesium addition improves the coronary outcome. The benefits guide separates ingredient evidence from the exact commercial formula.

What this means if your calcium score is high

Use the finding as a prompt for an informed discussion, not a replacement for cardiovascular care. Risk management may include lipid treatment, blood-pressure control, smoking cessation, activity and other measures according to the clinical assessment.

Do not stop a statin or other prescribed treatment because a supplement is described as clearing calcium. A calcium score and its change need clinical interpretation; more frequent scanning is not automatically useful.

Chest pain, sudden breathlessness or other acute cardiovascular symptoms require medical assessment. A supplement cannot serve as an urgent treatment.

A reasonable conclusion for the current evidence

MK-7-based interventions now have encouraging randomized evidence for slowing coronary-calcium progression in selected populations. Plaque removal, fewer heart attacks and universal prevention remain unestablished claims.

For nutrient context, use the K2 guide and D3/K2 pairing guide. For dose and anticoagulant issues, use combination dosage and safety. Those distinctions make the positive findings more useful by keeping the claim aligned with what was actually measured.

Related guides

• Vitamin D3, K2, Magnesium and Calcium for Bone Health

Research and sources

Explore the D3, K2 and magnesium research data center for study summaries, population and formulation details, limitations and original publication links. Source links throughout this guide point to the relevant evidence or official guidance.